Merck’s Japan unit files for approval of oral coronavirus treatment
![](https://japannews.yomiuri.co.jp/wp-content/uploads/DTMANAGE.000000020211203161942062-1.jpg)
Merck & Co.’s new antiviral medication molnupiravir
December 3, 2021
MSD K.K., a subsidiary of U.S. pharmaceutical company Merck & Co., filed an application for approval of the oral coronavirus treatment molnupiravir to the Health, Labor and Welfare Ministry on Friday.
If approved, it will be the first drug to be used in Japan for the treatment of the novel coronavirus.
The government wants the drug to be available for practical use by the end of this year.
It is said that the risk of serious illness is reduced if people with mild symptoms take the antiviral drug early in the course of the disease. In clinical trials, the drug was found to be effective in reducing the risk of serious illness by 30%, according to Merck.
The treatment has already been approved in Britain.
Japan has agreed to receive a supply of 1.6 million doses, on the assumption that the regulatory authority will swiftly approve the drug.
"Society" POPULAR ARTICLE
-
Japan Court OKs Sex Change without Surgery
-
3 Climbers Die On Mt. Fuji Within 2 Days Of Opening; Japan Police, Guides Urge Climbers To Prepare Well, Make Wise Decisions
-
Sex Crime Perpetrators Linked to U.S. Military in 166 Cases in Japan over 35 years; Local, Prefectural Governments Often Not Aware of Crimes
-
New Mt. Fuji Rules Reduce ‘Bullet Climbers’ by 90%; Access to Japan’s Iconic Peak Limited from Yamanashi Pref. Side
-
Tokaido Shinkansen Trains Suspended Between Hamamatsu and Nagoya Due to Accident; Resuming Services Expected Noon at Earliest
JN ACCESS RANKING